Lilly/Incyte pill beats placebo in mid-stage eczema trial

Sept 14 (Reuters) - Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.